Shares of ArQule (ARQL) have risen by 568% since I initially suggested readers purchase a pilot position due to there being "several ways to win" here. Shares have risen by 81% since my January update piece provided my outlook for 2019, as we looked forward to additional data for BTK inhibitor ARQ531 after initial signs of efficacy.
ROTY's 10-stock model account currently sports a 108% gain on its remaining shares, as we prudently took advantage of optimism ahead of upcoming data presentation at EHA (European Hematology Association) meeting to take some profits and risk off